{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:39:56Z","timestamp":1788550796670,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.athplu.2022.07.001","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T05:00:12Z","timestamp":1659416412000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels"],"prefix":"10.1016","volume":"50","author":[{"given":"Andreja","family":"Rehberger Likozar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9907-3522","authenticated-orcid":false,"given":"Miran","family":"\u0160ebe\u0161tjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.athplu.2022.07.001_bib1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/joim.13196","article-title":"Cardiovascular risk factors and lifestyle behaviours in relation to longevity: a Mendelian randomization study","volume":"289","author":"van Oort","year":"2021","journal-title":"J\u00a0Intern Med"},{"issue":"1","key":"10.1016\/j.athplu.2022.07.001_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J\u00a0Intern Med"},{"issue":"3","key":"10.1016\/j.athplu.2022.07.001_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.athplu.2022.07.001_bib4","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.athplu.2022.07.001_bib5","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.athplu.2022.07.001_bib6","first-page":"867","article-title":"Lipoprotein(a) and cardiovascular diseases - revisited","volume":"84","author":"Jang","year":"2020","journal-title":"Circ J Off J Jpn Circ Soc"},{"issue":"2","key":"10.1016\/j.athplu.2022.07.001_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00041433-199904000-00007","article-title":"Genetic architecture and evolution of the lipoprotein(a) trait","volume":"10","author":"Utermann","year":"1999","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"10.1016\/j.athplu.2022.07.001_bib8","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.ATV.12.10.1214","article-title":"Apo(a) isoforms predict risk for coronary heart disease. A study in six populations","volume":"12","author":"Sandholzer","year":"1992","journal-title":"Arterioscler Thromb J Vasc Biol"},{"issue":"19","key":"10.1016\/j.athplu.2022.07.001_bib9","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants","volume":"55","author":"Erqou","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.athplu.2022.07.001_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"24","key":"10.1016\/j.athplu.2022.07.001_bib11","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.athplu.2022.07.001_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.athplu.2022.07.001_bib13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/01.ATV.0000051384.43104.FC","article-title":"Endothelial dysfunction: a marker of atherosclerotic risk","volume":"23","author":"Bonetti","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.athplu.2022.07.001_bib14","first-page":"280","article-title":"Endothelial dysfunction predictor of structural changes of arterial wall in type I diabetes","volume":"25","author":"Poredos","year":"2006","journal-title":"Int Angiol J Int Union Angiol"},{"issue":"3","key":"10.1016\/j.athplu.2022.07.001_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacl.2018.02.004","article-title":"Improved endothelial function after short-term therapy with evolocumab","volume":"12","author":"Maulucci","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.athplu.2022.07.001_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.thromres.2020.07.049","article-title":"Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy","volume":"194","author":"Di Minno","year":"2020","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.athplu.2022.07.001_bib17","first-page":"114","article-title":"Vascular hypercontractility and endothelial dysfunction before development of atherosclerosis in moderate dyslipidemia: role for nitric oxide and interleukin-6","volume":"4","author":"Cavieres","year":"2014","journal-title":"Am J Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.athplu.2022.07.001_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00019501-200505000-00007","article-title":"Determinants of endothelial dysfunction and carotid intima-media thickness in combined hyperlipidemia","volume":"16","author":"Sebestjen","year":"2005","journal-title":"Coron Artery Dis"},{"issue":"1\u20132","key":"10.1016\/j.athplu.2022.07.001_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cca.2006.05.018","article-title":"Lipoprotein (a) as a determinant of arterial stiffness in elderly patients with type 2 diabetes mellitus","volume":"373","author":"Wakabayashi","year":"2006","journal-title":"Clin Chim Acta Int J Clin Chem"},{"issue":"4","key":"10.1016\/j.athplu.2022.07.001_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","article-title":"Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis","volume":"115","author":"Lorenz","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.athplu.2022.07.001_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.838466","article-title":"Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals","volume":"120","author":"Waters","year":"2009","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.athplu.2022.07.001_bib22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.athplu.2022.07.001_bib23","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J\u00a0Lipid Res"},{"issue":"12","key":"10.1016\/j.athplu.2022.07.001_bib24","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.athplu.2022.07.001_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","article-title":"Effect of alirocumab on lipoprotein(a) over \u22651.5 Years (from the phase 3 ODYSSEY program)","volume":"119","author":"Gaudet","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.athplu.2022.07.001_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism"},{"issue":"18","key":"10.1016\/j.athplu.2022.07.001_bib27","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.athplu.2022.07.001_bib28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.athplu.2022.07.001_bib29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.athplu.2022.07.001_bib30","article-title":"Ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery in clinical research","volume":"92","author":"Alley","year":"2014","journal-title":"J\u00a0Vis Exp JoVE"},{"issue":"12","key":"10.1016\/j.athplu.2022.07.001_bib31","first-page":"181","article-title":"LPA genotypes and haplotypes are associated with lipoprotein(a) levels but not arterial wall properties in stable post-coronary event patients with very high lipoprotein(a) levels","volume":"8","author":"Rehberger Likozar","year":"2021","journal-title":"J\u00a0Cardiovasc Dev Dis"},{"issue":"6","key":"10.1016\/j.athplu.2022.07.001_bib32","first-page":"451","article-title":"Global perspective on carotid intima-media thickness and plaque: should the current measurement guidelines be revisited?","volume":"38","author":"Saba","year":"2019","journal-title":"Int Angiol J Int Union Angiol"},{"issue":"4","key":"10.1016\/j.athplu.2022.07.001_bib33","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G\u2217Power 3.1: tests for correlation and regression analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav Res Methods"},{"issue":"18","key":"10.1016\/j.athplu.2022.07.001_bib34","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical Outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.athplu.2022.07.001_bib35","article-title":"Evolocumab, a PCSK9-monoclonal Antibody, rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia","volume":"9","author":"Leucker","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.athplu.2022.07.001_bib36","first-page":"E2256","article-title":"Effects of evolocumab on carotid intima-media thickness and clinical parameters in patients taking a statin","volume":"9","author":"Hirai","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.athplu.2022.07.001_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320959248","article-title":"Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial","volume":"11","author":"Breder","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.athplu.2022.07.001_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.11.019","article-title":"Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages","volume":"256","author":"Adorni","year":"2017","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.athplu.2022.07.001_bib39","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5551\/jat.14001","article-title":"Effect of statin therapy on the progression of common carotid artery intima-media thickness: an updated systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Huang","year":"2013","journal-title":"J\u00a0Atherosclerosis Thromb"},{"issue":"3","key":"10.1016\/j.athplu.2022.07.001_bib40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/ATVBAHA.113.300156","article-title":"Smoking, and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis","volume":"34","author":"Messner","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"10.1016\/j.athplu.2022.07.001_bib41","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jacc.2003.12.047","article-title":"The pathophysiology of cigarette smoking and cardiovascular disease: an update","volume":"43","author":"Ambrose","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.athplu.2022.07.001_bib42","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.athplu.2022.07.001_bib43","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","article-title":"Effect of evolocumab on coronary plaque composition","volume":"72","author":"Nicholls","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.athplu.2022.07.001_bib44","first-page":"289","article-title":"Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome","volume":"75","author":"Yano","year":"2020","journal-title":"J\u00a0Cardiol"},{"issue":"1","key":"10.1016\/j.athplu.2022.07.001_bib45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.21037\/cdt-20-684","article-title":"Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study","volume":"11","author":"Nicholls","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.athplu.2022.07.001_bib46","first-page":"2021","article-title":"The digital experience. Aug 27-31, 2021 late breaking trials in ACS: HUYGENS oral presentation","volume":"27","author":"Nicholls","year":"2021","journal-title":"ESC"},{"issue":"1","key":"10.1016\/j.athplu.2022.07.001_bib47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12944-021-01528-3","article-title":"Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography","volume":"20","author":"Gao","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"6","key":"10.1016\/j.athplu.2022.07.001_bib48","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jcmg.2020.01.021","article-title":"Adding alirocumab to rosuvastatin helps reduce the vulnerability of thin-cap fibroatheroma: an ALTAIR trial report","volume":"13","author":"Sugizaki","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"10","key":"10.1016\/j.athplu.2022.07.001_bib49","first-page":"2025","article-title":"Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome - the ODYSSEY J-IVUS trial","volume":"83","author":"Ako","year":"2019","journal-title":"Circ J Off J Jpn Circ Soc"},{"issue":"5","key":"10.1016\/j.athplu.2022.07.001_bib50","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.P080143","article-title":"Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D","volume":"59","author":"Basu","year":"2018","journal-title":"J\u00a0Lipid Res"}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089522000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089522000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:44:49Z","timestamp":1763023489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667089522000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":50,"alternative-id":["S2667089522000207"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2022.07.001","relation":{},"ISSN":["2667-0895"],"issn-type":[{"value":"2667-0895","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2022.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}